SLC22A3 and overactive bladder: It should be emphasized that this is the first report indicating that O-1602 has a therapeutic potential in an animal DO model; (5) administration of O-1602 reverses in vivo symptoms of overactive bladder via inhibition of VAChTA, OCT3, and CGRP.